medigraphic.com
ISSN 1561-302X (Print)

2020, Number 4

<< Back Next >>

Rev cubana med 2020; 59 (4)

Pulmonary lymphangioleiomyomatosis

Pino APP, Hernández ML

Language: Spanish
References: 11
Page: 1-5
PDF size: 251.02 Kb.


ABSTRACT

Introduction: Pulmonary lymphangioleiomyomatosis constitutes a challenge, both in its diagnostic management and in the care of complications. It is a rare disease characterized by the proliferation of smooth muscle around the bronchovascular and lymphatic structures and in the pulmonary interstitium, together with cystic dilation of the terminal air spaces.
Objective: To describe a diagnosed case of pulmonary lymphangioleiomyomatosis.
Case report: A case of pulmonary lymphangioleiomyomatosis is reported, which was clinically showed as recurrent pneumothorax. A definitive diagnosis was reached by performing a lung biopsy.
Discussion: Lymphangioleiomyomatosis is a rare entity that mainly affects women of childbearing age and is characterized by the presence of a diffuse cystic pattern. Its prevalence and incidence is unknown.
Conclusions: It can be concluded that the presence of spontaneous or recurrent pneumothorax in a woman of childbearing age, or pregnant, should be suspected lymphangioleiomyomatosis.


REFERENCES

  1. McCormack FX. Lymphangioleiomyomatosis: a clinical. Chest. 2008;133(2):507-16. https://doi.org/10.1378/chest.07-0898

  2. Pineda Bocanegra JL, Velázquez Cantillo KL, Maestre Serrano R, Santiago Henriquez EA. Pulmonary lymphangioleiomyomatosis, a rare lung disease: presentation of a clinical case. Rev Chil Enferm Respir. 2019;35:58-62.

  3. Johnson SR. Lymphangioleiomyomatosis. Eur Respir J. 2006;27(5):1056-654. https://doi.org/10.1183/09031936.06.00113303

  4. Harknett EC, Chang WY, Byrnes S, Johnson J, Lazor R, Cohen MM, et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM. 2011;104(11):971-9.

  5. Sánchez Lalana E, Lacoma Latre EM, Arévalo Durán M. Linfangioleiomatosis pulmonar. Revista Imagen diagnóstica. 2017;8(1):28-9.

  6. Freitas CSG, Baldi BG, Jardim C, Araujo MS, Sobral JB, Heiden GI, et al. Pulmonary hypertension in lymphangioleomyomatosis: prevalence, severity and the role of carbón monoxide difussion capacity as a screening method. Orphaned Journal of Rare disease. 2017;12(1):74-8.

  7. Yamanaka S, Mizobuchi T, Kurihara M. Two kinds of Cystic Lung lesions with Pulmonary Lynphangioleiomyomatosis in a male. Annals of Thoracic and cardiovascular Surgery. 2017;23(1):36-9.

  8. Sun X, Feng R, Zhang Y, Shi J, Xa KF. Coexistence of Pulmonary Lynphangioleiomyomatosis and Pulmonary angiomyolipoma. BMC Pulmonary Medicine. 2016;16(1):120-22.

  9. Nascimento ECTD. Balde BG, Mariani AW, Annomi R, Kairalla RA, Pimienta SP, et al. Inmunohistological features related to functional impairment in Lynphangioleiomyomatosis. Respiratory research. 2018;19(1):83-87.

  10. Martirossian A, Carrete L, Valle J, Valentine V, Durability of Sirolimus for Lymphangioleiomyomatosis. The American Journal of the Medical Sciences. 2017;354(6):603-07.

  11. Zhow L, Ouyang R, Luo H, Chen P, Peng Y. Efficacy of sirolimus for the prevention of recurrent pneumotorax in patients with Lynphangioleiomyomatosis: a case series. Orphanet J. Race Dr. 2018;13(1):168-72.




2020     |     www.medigraphic.com